TCGA-37-A5EM-01A-21R-A27Q-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 49
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.530
- G2M_CHECKPOINT+0.530
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.510
- MITOTIC_SPINDLE+0.360
- INTERFERON_ALPHA_RESPONSE+0.330
- NOTCH_SIGNALING+0.320
- WNT_BETA_CATENIN_SIGNALING+0.320
- TNFA_SIGNALING_VIA_NFKB+0.280
- ANGIOGENESIS+0.250
- MYC_TARGETS_V2+0.250
Top 10 suppressed
- FATTY_ACID_METABOLISM-0.390
- PEROXISOME-0.360
- BILE_ACID_METABOLISM-0.350
- ADIPOGENESIS-0.330
- PANCREAS_BETA_CELLS-0.330
- PROTEIN_SECRETION-0.330
- XENOBIOTIC_METABOLISM-0.300
- OXIDATIVE_PHOSPHORYLATION-0.270
- ANDROGEN_RESPONSE-0.230
- HEME_METABOLISM-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-85-A511-01A-21R-A262-07 | — | cohortSQ1 | 0.877 |
| 2 | SRR650185 | — | — | 0.854 |
| 3 | SRR934755 | — | — | 0.854 |
| 4 | TCGA-B6-A400-01A-11R-A239-07 | — | E | 0.843 |
| 5 | SRR650184 | — | — | 0.836 |
| 6 | SRR934821 | — | — | 0.830 |
| 7 | SRR10899983 | — | — | 0.826 |
| 8 | SRR8518214 | — | D | 0.816 |
| 9 | TCGA-85-8288-01A-11R-2296-07 | — | cohortSQ1 | 0.797 |
| 10 | TCGA-GC-A3YS-01A-11R-A23N-07 | — | — | 0.796 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.530 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.530 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.510 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.360 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.330 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.320 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.320 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.280 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.250 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.250 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.250 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.240 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.220 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.220 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.200 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.190 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.180 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.180 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.130 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.110 | Idelalisib | — uncovered |